Principal Financial Group Inc. grew its holdings in shares of Integra LifeSciences Holdings Corporation (NASDAQ:IART) by 3.1% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 489,221 shares of the life sciences company’s stock after buying an additional 14,833 shares during the period. Principal Financial Group Inc. owned 0.63% of Integra LifeSciences Holdings Corporation worth $24,696,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the company. FMR LLC raised its holdings in shares of Integra LifeSciences Holdings Corporation by 6.2% during the second quarter. FMR LLC now owns 8,084,562 shares of the life sciences company’s stock valued at $440,690,000 after buying an additional 468,678 shares during the last quarter. Capital Research Global Investors increased its stake in shares of Integra LifeSciences Holdings Corporation by 227.0% during the second quarter. Capital Research Global Investors now owns 3,897,288 shares of the life sciences company’s stock valued at $212,441,000 after acquiring an additional 2,705,488 shares during the period. Janus Henderson Group PLC acquired a new position in shares of Integra LifeSciences Holdings Corporation during the second quarter valued at approximately $112,068,000. Eagle Asset Management Inc. increased its stake in shares of Integra LifeSciences Holdings Corporation by 39.0% during the second quarter. Eagle Asset Management Inc. now owns 1,647,018 shares of the life sciences company’s stock valued at $89,778,000 after acquiring an additional 461,977 shares during the period. Finally, State Street Corp increased its stake in shares of Integra LifeSciences Holdings Corporation by 5.2% during the second quarter. State Street Corp now owns 1,575,125 shares of the life sciences company’s stock valued at $85,860,000 after acquiring an additional 78,082 shares during the period. 83.99% of the stock is currently owned by institutional investors.

A number of research firms recently commented on IART. Royal Bank Of Canada reiterated a “sector perform” rating and set a $50.00 price objective (up previously from $48.00) on shares of Integra LifeSciences Holdings Corporation in a research note on Thursday, November 9th. UBS AG reiterated a “buy” rating and set a $57.00 price objective on shares of Integra LifeSciences Holdings Corporation in a research note on Tuesday, October 31st. Wells Fargo & Company lowered shares of Integra LifeSciences Holdings Corporation from an “outperform” rating to a “market perform” rating in a research note on Sunday, October 29th. Jefferies Group LLC reiterated a “buy” rating and set a $56.00 price objective on shares of Integra LifeSciences Holdings Corporation in a research note on Sunday, October 29th. Finally, TheStreet lowered shares of Integra LifeSciences Holdings Corporation from a “b” rating to a “c+” rating in a research note on Thursday, October 26th. Seven equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $53.82.

In other Integra LifeSciences Holdings Corporation news, VP Richard D. Gorelick sold 1,500 shares of Integra LifeSciences Holdings Corporation stock in a transaction that occurred on Tuesday, November 14th. The shares were sold at an average price of $47.19, for a total value of $70,785.00. Following the transaction, the vice president now owns 21,665 shares in the company, valued at $1,022,371.35. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, Director Barbara B. Hill purchased 10,768 shares of the firm’s stock in a transaction on Tuesday, October 31st. The stock was acquired at an average price of $46.66 per share, for a total transaction of $502,434.88. Following the transaction, the director now owns 55,540 shares of the company’s stock, valued at approximately $2,591,496.40. The disclosure for this purchase can be found here. Insiders own 21.50% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Integra LifeSciences Holdings Corporation (IART) Stake Raised by Principal Financial Group Inc.” was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this article on another website, it was stolen and republished in violation of US & international copyright and trademark laws. The original version of this article can be read at https://www.thecerbatgem.com/2017/11/21/integra-lifesciences-holdings-corporation-iart-stake-raised-by-principal-financial-group-inc.html.

Integra LifeSciences Holdings Corporation (NASDAQ:IART) opened at $47.40 on Tuesday. The company has a debt-to-equity ratio of 1.26, a current ratio of 4.49 and a quick ratio of 3.39. The stock has a market cap of $3,732.39, a P/E ratio of 26.28, a price-to-earnings-growth ratio of 2.07 and a beta of 0.64. Integra LifeSciences Holdings Corporation has a 12-month low of $37.71 and a 12-month high of $56.42.

Integra LifeSciences Holdings Corporation (NASDAQ:IART) last posted its quarterly earnings results on Thursday, October 26th. The life sciences company reported $0.45 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.47 by ($0.02). The business had revenue of $278.83 million during the quarter, compared to analyst estimates of $286.00 million. Integra LifeSciences Holdings Corporation had a return on equity of 16.35% and a net margin of 4.52%. The company’s quarterly revenue was up 11.4% compared to the same quarter last year. During the same quarter last year, the firm posted $0.93 EPS. equities analysts forecast that Integra LifeSciences Holdings Corporation will post 1.87 EPS for the current year.

Integra LifeSciences Holdings Corporation Company Profile

Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions.

Institutional Ownership by Quarter for Integra LifeSciences Holdings Corporation (NASDAQ:IART)

Receive News & Stock Ratings for Integra LifeSciences Holdings Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences Holdings Corporation and related stocks with our FREE daily email newsletter.